Logo.png
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
February 20, 2025 08:30 ET | BioRestorative Therapies, Inc
– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase 2 Safety and Efficacy data reported to date – – May also...
Nurix.png
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
December 19, 2024 07:00 ET | Nurix Therapeutics, Inc.
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Joshua Hare
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
October 29, 2024 10:00 ET | Longeveron
Longeveron presents clinical data for stem cell therapy in Alzheimer's disease. Findings offer potential mechanistic and clinical insights.
Wa'el Hashad
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
July 17, 2024 08:00 ET | Longeveron
Longeveron announces FDA has granted Fast Track designation to cellular therapy Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease.
BioNTech und Duality
BioNTech und DualityBio erhalten Fast-Track-Status der FDA für Antikörper-Wirkstoff-Konjugat-Kandidat BNT324/DB-1311 bei Prostatakrebs
June 24, 2024 06:45 ET | BioNTech SE
Der Status basiert auf präklinischen Daten und Daten aus einer laufenden Phase-1/2-Studie für BNT324/DB-1311; vorläufige klinische Phase-1/2-Daten zeigten eine Anti-Tumor-Aktivität und ein...
BioNTech and Duality
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
June 24, 2024 06:45 ET | BioNTech SE
Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2...
finacialnews-logo-final-01 (2).png
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
June 11, 2024 08:45 ET | FN Media Group LLC
PALM BEACH, Fla., June 11, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - In the last twenty years, the amount of people with multiple sclerosis (MS) in the United States has more than...
Imugen.PNG
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
February 22, 2024 10:10 ET | Imugene Limited
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the company's immuno-oncology portfolio.
BioNTech und Duality
BioNTech und DualityBio erhalten Fast-Track-Status der FDA für innovativen Antikörper-Wirkstoff-Konjugat-Kandidat BNT325/DB-1305
January 31, 2024 06:45 ET | BioNTech SE
  Der Status basiert auf vorläufigen Daten zur Sicherheit und Wirksamkeit aus einer laufenden Phase-1/2-Studie in Patientinnen mit platinresistentem Epithelkarzinom der Eierstöcke, Eileiter...
BioNTech and Duality
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
January 31, 2024 06:45 ET | BioNTech SE
  Designation is based on preliminary safety and efficacy data from an ongoing Phase 1/2 trial in patients with platinum-resistant ovarian epithelial cancer, fallopian tube, or primary...